Last mentioned: Mar 26, 2026
King County Resolution
King County Council officially passes the resolution to decriminalize psychedelic mushrooms county-wide.
Anticipated Data Readout
Expected primary endpoint results for the COMP005 Phase 3 trial in TRD.
Fiscal Year End
Closed 2025 with a strategic focus on regulatory filing preparations.
Therapist Training Milestone
Completed training for over 500 facilitators to support Phase 3 delivery protocols.
Phase 3 Expansion
Compass increased the number of active clinical sites for COMP006 to over 50 globally.
WA SB 5263 Passed
Washington Governor signs a bill to create a psilocybin task force and pilot program.
Seattle Decriminalization
Seattle City Council passes a resolution to decriminalize the cultivation and possession of psychedelic plants.
King County has officially passed a resolution to decriminalize the possession and use of psychedelic mushrooms, joining a growing list of Pacific Northwest jurisdictions. This move reflects a significant shift toward viewing psilocybin through a public health lens, potentially paving the way for expanded clinical research and therapeutic access in the region.
Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.